Joseph P Rogers

US Patent:

20060205024, Sep 14, 2006

Filed:

Mar 8, 2006

Appl. No.:

11/371667

Inventors:

Joseph Rogers - Glendale AZ, US
Rena Li - Scottsdale AZ, US
Diego Mastroeni - Surprise AZ, US
Andrew Grover - El Mirage AZ, US
Marwan Sabbagh - Scottsdale AZ, US

International Classification:

G01N 33/537
G01N 33/53
G01N 33/543
G01N 33/00

US Classification:

435007920, 436086000

Abstract:

A method or technique of detecting, diagnosing, monitoring, and evaluating a neurodegenerative disease, such as Alzheimer's disease, in a human body fluid is disclosed. The invention provides for a method of detecting amyloid peptides associated with erythrocytes and amyloid peptide complement complexes, as a diagnostic test for the detection, monitoring, evaluation or diagnosis of Alzheimer's disease and amyloid-based neurodegenerative diseases. More specifically the invention is directed to a method for detecting presence and amount of amyloid peptides such as amyloid beta (“Aβ”) and Aβ complement complexes, and related complement complexes and compounds with a role in neurodegenerative diseases, in an erythrocyte fraction of a human bodily fluid.

US Patent:

20110086925, Apr 14, 2011

Filed:

Jun 9, 2010

Appl. No.:

12/797591

Inventors:

Diego Mastroeni - Surprise AZ, US
Joseph Rogers - Glendale AZ, US
Andrew Grover - Peoria AZ, US
Paul D. Coleman - New River AZ, US

International Classification:

A61K 47/00
G01N 33/53
C12Q 1/68
A61P 25/28

US Classification:

514789, 435 71, 435 6

Abstract:

Various embodiments provide methods for the detection, the diagnosis, and/or the progression monitoring of Alzheimer's disease by observing the epigenetic markers in leukocytes. Methods for determining a state of Alzheimer's disease are provided. Accordingly, these methods can comprise the steps of placing a sample comprising at least one blood component onto a substrate labeling the sample to identify at least one epigenetic marker; determining an amount of the at least one epigenetic marker; comparing the amount to a reference value; and determining a state of Alzheimer's disease.

US Patent:

51927535, Mar 9, 1993

Filed:

Apr 23, 1991

Appl. No.:

7/689499

Inventors:

Patrick L. McGeer - Vancouver, B. C., CA
Joseph Rogers - Glendale AZ
John Sibley - Saskatoon, Saskatchewan, CA
Edith McGeer - Vancouver, B. C., CA

International Classification:

A61K 3160
A61K 31615
A61K 3154
A61K 3144
A61K 31425
A61K 3142
A61K 31415
A61K 3140
A61K 3138
A61K 31195
A61K 3119

US Classification:

514159

Abstract:

This invention pertains to the novel use of anti-rheumatoid arthritic drugs in the treatment of dementia. A method of treating dementia in human beings which comprises administering to the human being a therapeutic amount of a non-steroidal anti-inflammatory drug (NSAID) which has the ability to inhibit prostaglandin synthesis in the human being.

US Patent:

20160047801, Feb 18, 2016

Filed:

May 7, 2015

Appl. No.:

14/706835

Inventors:

- Sun City AZ, US
Joseph Rogers - Glendale AZ, US
Andrew Grover - Peoria AZ, US
Paul D. Coleman - New River AZ, US

International Classification:

G01N 33/53
G01N 33/68

Abstract:

Various embodiments provide methods for the detection, the diagnosis, and/or the progression monitoring of Alzheimer's disease by observing the epigenetic markers in leukocytes. Methods for determining a state of Alzheimer's disease are provided. Accordingly, these methods can comprise the steps of placing a sample comprising at least one blood component onto a substrate labeling the sample to identify at least one epigenetic marker; determining an amount of the at least one epigenetic marker; comparing the amount to a reference value; and determining a state of Alzheimer's disease.

US Patent:

20140220572, Aug 7, 2014

Filed:

Mar 25, 2014

Appl. No.:

14/225155

Inventors:

- Sun City AZ, US
Joseph Rogers - Glendale AZ, US
Andrew Grover - Peoria AZ, US
Paul D. Coleman - New River AZ, US

International Classification:

C12Q 1/68

US Classification:

435 611

Abstract:

Various embodiments provide methods for the detection, the diagnosis, and/or the progression monitoring of Alzheimer's disease by observing the epigenetic markers in leukocytes. Methods for determining a state of Alzheimer's disease are provided. Accordingly, these methods can comprise the steps of placing a sample comprising at least one blood component onto a substrate labeling the sample to identify at least one epigenetic marker; determining an amount of the at least one epigenetic marker; comparing the amount to a reference value; and determining a state of Alzheimer's disease.